RxDoctor Payments Data

Heather McDonald, DO

Family Medicine · San Dimas, CANPI 1003142886

Payments from drug & device makers

$1,627in general payments, 2019–2025

Across 81 payments — averaging $20.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$303
  • Boehringer Ingelheim$230
  • Novo Nordisk$181
  • Amarin Pharma, Inc.$170
  • Abbott$117
  • AbbVie$110
  • plus $515 from 14 others

What the payments were for

  • Food & beverage$1,627100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,627 in reported general payments places this provider in the 80th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$70,902
Medicare patients
123
Services billed
715

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin49$56,397
FarxigaDapagliflozin Propanediol31$33,436
JanuviaSitagliptin Phosphate29$29,783
OzempicSemaglutide24$27,184
EliquisApixaban19$20,621
LinzessLinaclotide16$12,360
MounjaroTirzepatide12$12,332
Breo ElliptaFluticasone/Vilanterol12$4,747
Fluticasone-SalmeterolFluticasone Propion/Salmeterol13$3,005
Wixela InhubFluticasone Propion/Salmeterol16$3,004
Levothyroxine Sodium200$2,764
Liothyronine Sodium70$2,032
Gabapentin123$1,997
Atorvastatin Calcium223$1,984
SynthroidLevothyroxine Sodium25$1,722

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$230$56,39749 claims
AstraZenecaFarxiga$29$33,43631 claims
Novo NordiskOzempic$181$27,18424 claims
PfizerEliquis$45$20,62119 claims
AbbVieLinzess, Synthroid$110$14,08241 claims
Lilly USA, LLCMounjaro$303$12,33212 claims
GSKBreo Ellipta$24$4,74712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 10,533 family medicine providers in California.

Other family medicine in San Dimas

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →